# Phase 1/2 mesothelioma trials recruiting: 20 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials in phase 1/2 for mesothelioma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 mesothelioma trials: 20 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/mesothelioma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 20
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 21, 2026 | NCT07885319 | Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma | Ruijin Hospital | Phase 1/2 | Recruiting | Malignant Pleural Mesothelioma, Advanced | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07885319) |
| July 15, 2026 | NCT07705074 | FAPI PET Imaging - An Exploratory Study | Sponsor not shown (see the record) | Phase 1/2 | Not yet recruiting | Thyroid Pathology, Head and Neck Cancer (H&N), Sinonasal Tract Tumor, Sarcoidosis, Thyroid Cancer, Breast Cancer... | 770 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07705074) |
| May 4, 2026 | NCT07563738 | A 2-part Phase 1/2 Open-label Trial on ODM-212 | Orion Corporation, Orion Pharma | Phase 1/2 | Recruiting | Mesothelioma, Pancreatic Cancer, NSCLC (Advanced Non-small Cell Lung Cancer) | 229 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07563738) |
| April 6, 2026 | NCT07510815 | Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma | Beijing Biotech | Phase 1/2 | Recruiting | Malignant Pleural Mesotheliomas | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07510815) |
| December 15, 2025 | NCT07282873 | Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors | TYK Medicines, Inc | Phase 1/2 | Not yet recruiting | Solid Tumor Malignancies, Malignant Mesothelioma (MM) | 219 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07282873) |
| August 20, 2025 | NCT07131345 | Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma | National Cancer Center, China | Phase 1/2 | Not yet recruiting | Malignant Mesothelioma, Mesothelioma | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07131345) |
| August 13, 2025 | NCT07121374 | NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study | University Hospital, Antwerp | Phase 1/2 | Recruiting | Pleural Epithelioid Mesothelioma, Mesothelioma; Pleura, Neoadjuvant Chemoimmunotherapy | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07121374) |
| November 29, 2024 | NCT06710756 | Lead-212 PSV359 Therapy for Patients With Solid Tumors | Perspective Therapeutics | Phase 1/2 | Recruiting | Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Ovarian Cancer, Head and Neck... | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06710756) |
| August 22, 2024 | NCT06566079 | Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors | InSilico Medicine Hong Kong Limited | Phase 1/2 | Recruiting | Malignant Mesothelioma, Metastatic Malignant Solid Tumor, Advanced Solid Tumor | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06566079) |
| April 12, 2024 | NCT06362369 | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | 7 Hills Pharma, LLC | Phase 1/2 | Recruiting | Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis, Pleural Mesothelioma, Renal Cell Carcinoma, MSI-High... | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06362369) |
| February 2, 2024 | NCT06239194 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | ModeX Therapeutics, An OPKO Health Company | Phase 1/2 | Recruiting | Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gastric... | 330 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06239194) |
| July 13, 2023 | NCT05944237 | HTL0039732 in Participants With Advanced Solid Tumours | Cancer Research UK | Phase 1/2 | Recruiting | Neoplasms, Prostatic Neoplasms, Castration-Resistant, Stomach Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms... | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05944237) |
| July 6, 2023 | NCT05932199 | Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma | Baylor College of Medicine | Phase 1/2 | Recruiting | Mesothelioma | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05932199) |
| March 13, 2023 | NCT05765084 | Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid... | University Hospital, Antwerp | Phase 1/2 | Recruiting | Malignant Pleural Mesothelioma | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05765084) |
| February 17, 2023 | NCT05732831 | Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors | Tango Therapeutics, Inc. | Phase 1/2 | Recruiting | Locally Advanced Solid Tumor | 225 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05732831) |
| October 13, 2022 | NCT05579366 | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) | Genmab | Phase 1/2 | Recruiting | High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube... | 952 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05579366) |
| July 20, 2021 | NCT04969315 | TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma | Portage Biotech | Phase 1/2 | Recruiting | Renal Cell Cancer, Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer, Pleural Mesothelioma Malignant | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04969315) |
| December 11, 2020 | NCT04665206 | Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors | Vivace Therapeutics, Inc | Phase 1/2 | Recruiting | Solid Tumor, Adult, Mesothelioma, NSCLC, Pleural Mesothelioma, Non-Pleural Mesothelioma, Non Small Cell Lung Cancer... | 474 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04665206) |
| September 26, 2019 | NCT04104776 | A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | Novartis Pharmaceuticals | Phase 1/2 | Recruiting | Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms... | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04104776) |
| June 14, 2018 | NCT03556228 | VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | VM Oncology, LLC | Phase 1/2 | Recruiting | Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer... | 242 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03556228) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| University Hospital, Antwerp | 2 |
| National Cancer Center, China | 1 |
| Portage Biotech | 1 |
| Perspective Therapeutics | 1 |
| Baylor College of Medicine | 1 |
| Cancer Research UK | 1 |
| Ruijin Hospital | 1 |
| InSilico Medicine Hong Kong Limited | 1 |
| Vivace Therapeutics, Inc | 1 |
| ModeX Therapeutics, An OPKO Health Company | 1 |
| VM Oncology, LLC | 1 |
| Tango Therapeutics, Inc. | 1 |
| [Orion Corporation, Orion Pharma](https://specstream.ai/data/clinical-trials/company/orion-corporation-orion-pharma) | 1 |
| [Beijing Biotech](https://specstream.ai/data/clinical-trials/company/beijing-biotech) | 1 |
| TYK Medicines, Inc | 1 |
| [Genmab](https://specstream.ai/data/clinical-trials/company/genmab) | 1 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 1 |
| 7 Hills Pharma, LLC | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 12 |
| China | 5 |
| United Kingdom | 3 |
| France | 3 |
| Spain | 3 |
| Belgium | 2 |
| Switzerland | 2 |
| South Korea | 2 |
| Australia | 1 |
| Puerto Rico | 1 |
| Denmark | 1 |
| Finland | 1 |
| Japan | 1 |
| Italy | 1 |
| Poland | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Dermatology practices in the United States](https://specstream.ai/data/businesses/dermatology-practices/united-states)
- [Warehouses in the United States](https://specstream.ai/data/businesses/warehouses/united-states)
- [Occupational safety services in the United States](https://specstream.ai/data/businesses/occupational-safety-services/united-states)
- [Endocrinology practices in the United States](https://specstream.ai/data/businesses/endocrinology-practices/united-states)
- [Aircraft parts suppliers in the United States](https://specstream.ai/data/businesses/aircraft-parts-suppliers/united-states)
- [Personal injury law firms in the United States](https://specstream.ai/data/businesses/personal-injury-law-firms/united-states)
